Top

Published in:

01-06-2010 | Review

Addressing the age-related needs of osteoporotic patients with strontium ranelate

Author: S. Boonen

Published in: Osteoporosis International | Special Issue 2/2010

Abstract

Osteoporotic fractures are associated with significant morbidity and mortality with an enormous impact on society and the lives of affected individuals. Age and menopause are the two main risk factors for osteoporosis, and women therefore need to be particularly concerned about bone loss at this time. In addition to suffering fracture-associated morbidity, women with prior fractures have an increased risk of future fractures. Young postmenopausal women who have experienced a fragility fracture therefore face a lifetime of fracture risk. The burden of fractures increases with advancing age, and bone mineral density declines, with women over the age of 80 years having the highest risk of fracture because of their high prevalence of osteoporosis and an increased likelihood of falls. A number of antiosteoporotic agents are available for the treatment of postmenopausal women including bisphosphonates, raloxifene, teriparatide, and strontium ranelate. For osteoporotic drugs to be beneficial in reducing the burden of fractures, they need to be effective against fracture in all age groups of postmenopausal women. With its dual mode of action, strontium ranelate is the first agent with proven early and sustained antifracture efficacy in all age groups including young postmenopausal women and those over 80 years. Evidence is now available to show that all women, including the elderly, can benefit from treatment to prevent further bone loss and restore lost bone to decrease the risk of further fractures. By implementing procedures to identify those at greatest risk and initiate safe and effective treatments, physicians can significantly improve patients' quality of life.

National Institute for Health and Clinical Excellence (2009) Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. NICE technology appraisal guidance 160. Available via: http//:www.nice.org.uk/TA160. Accessed December 2009

Melton LJ 3rd, Thamer M, Ray NF, Chan JK, Chesnut CH 3rd, Einhorn TA, Johnston CC, Raisz LG, Silverman SL, Siris ES (1997) Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 12:16–23CrossRefPubMed

Riggs BL, Melton LJ 3rd (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17(Suppl 5):505S–511SCrossRefPubMed

Gullberg B, Johnell O, Kanis JA (1997) Worldwide projections for hip fracture. Osteoporos Int 7:407–413CrossRefPubMed

Dennison E, Mohamed MA, Cooper C (2006) Epidemiology of osteoporosis. Rheum Dis Clin North Am 32:617–629CrossRefPubMed

Johnell O, Kanis JA (2004) An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 15:897–902CrossRefPubMed

Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229–238CrossRefPubMed

van Staa TP, Dennison EM, Leufkens HG, Cooper C (2001) Epidemiology of fractures in England and Wales. Bone 29:517–522CrossRefPubMed

Looker AC, Orwoll ES, Johnston CC Jr et al (1997) Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 12:1761–1768CrossRefPubMed

10.

Kanis JA, Adami S (1994) Bone loss in the elderly. Osteoporos Int 4(Suppl 1):59–65CrossRefPubMed

11.

Seeman E, Vellas B, Benhamou CL et al (2006) Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women aged eighty years and over. J Bone Miner Res 21:1113–1120CrossRefPubMed

12.

Cummings SR, Melton JR III (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767CrossRefPubMed

13.

Grados F, Marcellib C, Dargent-Molinac P, Roux C, Vergnola JF, Meuniere PJ, Fardellonea P (2004) Prevalence of vertebral fractures in French women older than 75 years from the EPIDOS study. Bone 34:362–367CrossRefPubMed

14.

Cooper C, Campion G, Melton LJ 3rd (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285–289CrossRefPubMed

15.

Rizzoli R, Bruyere O, Cannata-Andia JB, Devogelaer JP, Lyritis G, Ringe JD, Vellas B, Reginster JY (2009) Management of osteoporosis in the elderly. Curr Med Res Opin 25:2373–2387CrossRefPubMed

16.

Rolland Y, Abellan van Kan G, Bénétos A, Blain H, Bonnefoy M, Chassagne P et al (2008) Frailty, osteoporosis and hip fracture: causes, consequences and therapeutic perspectives. J Nutr Health Aging 12:335–346CrossRefPubMed

17.

Ensrud KE, Ewing SK, Taylor BC, Fink HA, Stone KL, Cauley JA, for the Study of Osteoporotic Fractures Research Group et al (2007) Frailty and risk of falls, fracture and mortality in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci 62:744–751PubMed

18.

Nevitt MC, Ettinger B, Black DM et al (1998) The association of radiographically detected vertebral fracture with back pain and function: a prospective study. Ann Intern Med 128:793–800PubMed

19.

Cummings SR, Nevitt MC, Browner WS et al (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767–773CrossRefPubMed

20.

Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382CrossRefPubMed

21.

Center JR, Bliuc D, Nguyen TV, Eisman JA (2007) Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 297:387–394CrossRefPubMed

22.

Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556–561CrossRefPubMed

23.

Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Melton LJ (2002) Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 50:1644–1650CrossRefPubMed

24.

Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C (2009) Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 20:1633–1650CrossRefPubMed

25.

Richmond J, Aharonoff GB, Zuckerman JD, Koval KJ (2003) Mortality risk after hip fracture. J Orthop Trauma 17:53–56CrossRefPubMed

26.

Boonen S, Singer AJ (2008) Osteoporosis management: impact of fracture type on cost and quality of life in patients at risk for fracture. Curr Med Res Opin 24:1781–1788CrossRefPubMed

27.

Salkeld G, Cameron ID, Cumming RG, Easter S, Seymour J, Kurrle SE, Quine S (2000) Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ 320:341–346CrossRefPubMed

28.

von Friesendorff M, Besjakov J, Akesson K (2008) Long-term survival and fracture risk after hip fracture: a 22-year follow-up in women. J Bone Miner Res 23:1832–1841CrossRef

29.

Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. The European foundation for osteoporosis and bone disease. Osteoporos Int 7:390–406CrossRefPubMed

30.

Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475CrossRefPubMed

31.

Hamdy NAT (2007) Novel approaches to living bone. In: Roux C (ed) The living skeleton. Kluwer, France, pp 27–40

32.

Seeman E (2007) The size, shape, spatial distribution and strength of bone in adulthood. In: Roux C (ed) The living skeleton. Kluwer, France, pp 27–40

33.

Hunter DJ, Sambrook PN (2000) Bone loss: epidemiology of bone loss. Arthritis Res 2:441–445CrossRefPubMed

34.

Felsenberg D, Boonen S (2005) The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 27:1–11CrossRefPubMed

35.

Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397CrossRefPubMed

36.

European Medicines Agency (2010) Committee for Medicinal Products for Human Use summary of positive opinion for Prolia. London, 17 December 2009. Available at: http://www.ema.europa.eu/pdfs/human/opinion/Prolia_77616809en.pdf. Accessed March 2010

37.

Marie PJ (2006) Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation. Curr Opin Rheumatol 18(Suppl 1):S11–S15CrossRefPubMed

38.

Meunier PJ, Reginster JY (2003) Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporosis Int 14(Suppl 3):S66–S76

39.

Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468CrossRefPubMed

40.

Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TROPOS study. J Clin Endocrinol Metab 90:2816–2822CrossRefPubMed

41.

Roux C, Reginster JY, Fechtenbaum J, Kolta S, Sawicki A, Tulassay Z et al (2006) Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 21:536–542CrossRefPubMed

42.

Collette J, Bruyère O, Kaufman JM, Lorenc R, Felsenberg D, Spector TD et al (2010) Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover. Osteoporos Int 21:233–241CrossRefPubMed

43.

Roux C, Fechtenbaum J, Kolta S, Isaia G, Andia JB, Devogelaer JP (2008) Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis 67:1736–1738CrossRefPubMed

44.

Arden N, editor. Risk factors for fracture. In: Osteoporosis. London, UK: Remedica; 2006. pp. 55–73

45.

Epstein S (2007) Is treatment of early postmenopausal women with bisphosphonates justified? Int J Clin Pract 61:963–971CrossRefPubMed

46.

Seeman E, Boonen S, Borgström F, Vellas B, Aquino J-P, Semler J et al (2010) Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life years in women over 80 years of age. Bone 46:1038–1042CrossRefPubMed

47.

Boonen S, McClung MR, Eastell R, El-Hajj Fuleihan G (2004) Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 52:1832–1839CrossRefPubMed

48.

Boonen S, Marin F, Mellstrom D et al (2006) Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 54:782–789CrossRefPubMed

49.

Ringe JD, Doherty JG (2009) Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int [in press]

50.

Ismail AA, Cooper C, Felsenberg D et al (1999) Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int 9:206–213CrossRefPubMed

51.

Lips P, van Schoor NM (2005) Quality of life in patients with osteoporosis. Osteoporos Int 16:447–455CrossRefPubMed

52.

Marquis P, Roux C, Diaz-Curiel M (2007) Long-term beneficial effects of strontium ranelate on the quality of life in patients with vertebral osteoporosis (SOTI study). Osteoporos Int 18(suppl 1):S123

53.

Marquis P, Roux C, De la Loge C, Diaz-Curiel M, Cormier C, Isaia G et al (2008) Strontium ranelate prevents quality of life impairment in postmenopausal women with established vertebral osteoporosis. Osteoporos Int 19:503–510CrossRefPubMed

54.

Feldstein A, Elmer PJ, Orwoll E, Herson M, Hillier T (2003) Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 163:2165–2172CrossRefPubMed

Title: Addressing the age-related needs of osteoporotic patients with strontium ranelate
Author: S. Boonen
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue Special Issue 2/2010
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-010-1231-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Addressing the age-related needs of osteoporotic patients with strontium ranelate

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 2/2010

Comparing and contrasting the effects of strontium ranelate and other osteoporosis drugs on microarchitecture

Fracture prevention in osteoporosis: assessing risks, providing solutions

Strontium ranelate: an effective solution for diverse fracture risks

Microarchitecture in focus

Development and use of FRAX® in osteoporosis

Osteoporosis: disease severity and consequent fracture management